ASP同位素公司美股招股说明书(2025-07-24版)

Common Stock Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On July23, 2025, the lassale price of shares of our common stock on Nasdaq was $10.00 per share. supplement and in our filings with the Securities and Exchange Commission that are incorporated by reference in this psupplement and the accompanying prospectus to read about factors you should consider before buying shares of our common s Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved Per Share Underwriting Discounts and Commissions(1)$0.48Proceeds to ASP Isotopes Inc. (before expenses)$7.52________________________________________ The underwriters expect to deliver the shares to purchasers on or about July25, 2025. writing prospectus that we have authorized for use in connection with this offering, and the information incorporated by reference asunder the headings “Where You Can Find More Information” and “Incorporation of Certain Information by Reference” in this psupplement. These documents contain important information that you should consider when making your investment decision.This prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement on Form S-3 (File286860) that was declared effective by the Securities and Exchange Commission, or the “SEC,” on May30, 2025. This document is cof two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to, aninformation contained in, the accompanying prospectus and the documents incorporated by reference into this prospectus supplemenaccompanying prospectus. The second part, the accompanying prospectus, provides more general information, some of which may no updated and superseded. In other words, in case of a conflict or inconsistency between information contained in this prospectus suppleinformation in the accompanying prospectus or incorporated by reference into this prospectus supplement, you should rely on the incontained in the document that was filed later.We have not, and the underwriters have not, authorized anyone to provide any information other than that contained or incorpreference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus that we have authorizedconnection with this offering. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the dincorporated by reference into this prospectus supplement and the accompanying prospectus, and in any free writing prospectus thaauthorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, Unless the context otherwise indicates, references in this prospectus to “we,” “our” and “us” refer to ASP Isotopes Inc., acorporation, and its consolidated subsidiaries taken as a whole. accompanying prospectus and any free writing prospectus, as well as the information incorporated by reference, before deciding winvest in shares of our common stock. You should pay special attention to the “Risk Factors” section beginning on page S-7 of this psupplement and in our Annual Report on Form 10-K for the year ended December 31, 2024, as revised or supplemented by our suSEC filings, incorporated by reference into this prospectus supplement and the accompanying prospectus, along with our con OverviewWe are a development stage advanced materials company dedicated to the development of technology and processesuccessful, will allow for the enrichment of natural isotopes into higher concentration products, which could be used in several indusproprietary technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment technology (“QE techare designed to enable the production of isotopes used in several industries. Our initial focus is on the production and commercial product during 2025. In addition, we have started planning additional isotope enrichment plants both in South Africa and in other juriincluding Iceland and the United States. We believe the C-14 we may produce using the ASP technology could be used in the develonew pharmaceuticals and agrochemicals. We believe the Si-28 we may produce using the ASP technology may be used to createsemiconductors and in quantum computing. We believe the Yb-176 we may produce using the QE technology may be used potential use in the healthcare end market, Germanium 70/72/74 for potential use in the semiconductor end market, and Chlorinpotential use in the nuclear energy end market. We are also considering the future development of QE technology for the separation o64, Gadolinium-160, Ytterbium-171, Lithium 6 and Lithium7.We are currently pursuing an initiative to apply our enrichment technologies to the enrichment of Ura